Sex: M
Vaccine: COVID19
Symptoms: Dermatitis atopic, Fungal infection, Oropharyngeal pain, Pruritus, Rash
Clinical narrative: flare ups (atopic dermatitis); broke out in a rash everywhere; breakthrough itching; will be sometimes raw at the site; it/the injection hurts sometimes but not every time; tonsil soreness the comes and goes; yeast infection; This is a spontaneous report received from a Consumer or other non HCP from License Party. Other Case identifier(s): 2022SA478824 (Sanofi).  A 65-year-old male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPIXENT), first regimen since 02Nov2022) at 600 mg 1x/day, subcutaneous, second regimen since 16Nov2022) at 300 mg (300 mg qow (every other week)), subcutaneous and third regimen since 06Apr2023) at 300 mg (300 mg qow) for dermatitis atopic. The patient's relevant medical history included: "Pruritus" (unspecified if ongoing); "Atopic dermatitis" (unspecified if ongoing); "Eczema" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series completed; Unknown manufacturer), for COVID-19 immunisation. The following information was reported: FUNGAL INFECTION (non-serious) with onset 23Jul2023, outcome "recovering", described as "yeast infection"; DERMATITIS ATOPIC (non-serious), outcome "not recovered", described as "flare ups (atopic dermatitis)"; RASH (non-serious), outcome "not recovered", described as "broke out in a rash everywhere"; PRURITUS (non-serious), outcome "not recovered", described as "breakthrough itching"; VACCINATION SITE REACTION (non-serious), outcome "not recovered", described as "will be sometimes raw at the site"; VACCINATION SITE PAIN (non-serious), outcome "not recovered", described as "it/the injection hurts sometimes but not every time"; OROPHARYNGEAL PAIN (non-serious), outcome "unknown", described as "tonsil soreness the comes and goes". Therapeutic measures were taken as a result of dermatitis atopic, rash, pruritus, fungal infection. Additional information: It was reported "I am still itching like crazy but happy to get some help". The nurse was unable to obtain other details. He is having outbreaks at the 2-week period of his Eczema. He spoke with the doctor, and she is like pushing the limit of his medication with his current weight which is 220lbs. There is not a greater dosage that the doctor can give him at this point. Doctor has prescribed him a topical cream for his flare ups - Halobetasol propionate. The injection does hurt when he does it. It will be sometimes raw at the site. The patient experiences minor additional outbreaks and itchiness; he experiences tonsil soreness that comes and goes, he is unsure if it is related to Dupixent (Dupilumab) or related to his allergies; and he stated that Dupixent was not enough by itself to help with his condition. Dupixent runs out before 2 weeks; he starts to breakout on both legs before 2 days before his next scheduled dose; he has used topical steroids which has helped; stated that his provider believes that due to his total body mass, he may require additional dose of Dupixent, like 350 mg. The patient reports he has breakthrough itching 2 or 3 days before his next injection and has to augment with halobetasol cream. He experiences break outs three to four days before his next Dupixent. Patient also reports he broke out in a rash everywhere after taking Covid booster shot and has no plans on taking it again. It was further reported that the patient has been experiencing a yeast infection on and off for the past month, so it started around 23Jul2023. The patient was treated with ULOBETASOL PROPIONATE (Halobetasol propionate) for atopic dermatitis flare, pruritus and rash; JARDIANCE (Empagliflozin) for fungal infection.   Reporter causality: Not reported for all events.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.